phrykt

Kura Oncology, Inc. (KURA): who owns it and who trades it

As of Nov 16, 2026, KURA insiders reported 34 open-market sales worth $3.3M and 4 purchases worth $3.9M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mollie Leoni (Chief Medical Officer), with $1.3M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Kura Oncology

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns KURA

218 funds and institutions reported KURA shares worth $962M at the end of Q2 2026, about 99% of the company. The largest holder is BlackRock, Inc. with 11.9%.

Funds and institutions (13F) 99%Everyone else 1%

10 largest owners, by share of the company

BlackRock, Inc.11.9%
Montanova Capital, LLC9.7%
Bvf Inc9.6%
State Street Corp6.0%
Vanguard Capital Management LLC4.4%
Armistice Capital, LLC4.2%
AQR Capital Management LLC3.5%
Goldman Sachs Group Inc2.6%
Geode Capital Management, LLC2.5%
Alethea Capital Management, LLC2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.10.51M11.90%$115M+9%
Montanova Capital, LLC8.58M9.71%$94.1MNo change
Bvf Inc8.45M9.56%$92.7MNo change
State Street Corp5.33M6.03%$58.5M+18%
Vanguard Capital Management LLC3.92M4.43%$43M+3%
Armistice Capital, LLC3.68M4.16%$40.3M-2%
AQR Capital Management LLC3.13M3.54%$34.3M+47%
Goldman Sachs Group Inc2.27M2.56%$24.8M+58%
Geode Capital Management, LLC2.23M2.52%$24.5M+10%
Alethea Capital Management, LLC2.17M2.45%$23.8M+42%
Prosight Management, LP2.02M2.29%$22.2M-40%
Deep Track Capital, LP1.98M2.24%$21.7M-25%
Renaissance Technologies LLC1.66M1.88%$18.3M+5%
Arrowstreet Capital, Limited Partnership1.41M1.60%$15.5M–
Vanguard Portfolio Management LLC1.33M1.51%$14.6M+8%
Nan Fung Trinity (hk) Ltd1.17M1.33%$12.9M+10%
Qube Research & Technologies Ltd1.17M1.32%$12.8M-29%
Dimensional Fund Advisors LP1.17M1.32%$12.8M-18%
Bank of America Corp1.16M1.31%$12.7M-6%
Morgan Stanley1.16M1.31%$12.7M-0%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, KURA insiders reported $3.9M of open-market purchases and $3.3M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$3.9M
4 trades, 1 people
Sales, 12 months
$3.3M
34 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 16, 2026
Filed Nov 16, 2026

Purchases and sales by month

$2.4M$2.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 16, 2026Troy Edward WilsonCEOPurchase101,119$7.42$750KForm 4
Nov 13, 2026Troy Edward WilsonCEOPurchase98,881$7.63$754KForm 4
Sep 29, 2026Kathleen FordChief Operating OfficerSale3,668$10.75$39.4KForm 4
Sep 29, 2026Mollie LeoniChief Medical OfficerSale28,802$10.75$310KForm 4
Sep 29, 2026Brian T. PowlChief Commercial OfficerSale15,430$10.75$166KForm 4
Sep 28, 2026Teresa Brophy BairChief Legal OfficerSale8,442$10.50$88.6KForm 4
Sep 28, 2026Kathleen FordChief Operating OfficerSale6,906$10.50$72.5KForm 4
Sep 28, 2026Mollie LeoniChief Medical OfficerSale12,448$10.50$131KForm 4
Sep 28, 2026Thomas James DoyleVice presidentSale4,607$10.50$48.4KForm 4
Sep 28, 2026Brian T. PowlChief Commercial OfficerSale9,020$10.50$94.7KForm 4
Sep 28, 2026Brian T. PowlChief Commercial OfficerSale8,000$10.56$84.5KForm 4
Sep 24, 2026Francis BurrowsChief Scientific OfficerSale20,726$10.83$224KForm 4
Aug 24, 2026Troy Edward WilsonCEOPurchase100,000$12.39$1.2MForm 4
Aug 21, 2026Brian T. PowlChief Commercial OfficerSale4,345$11.89$51.7KForm 4
Aug 19, 2026Teresa Brophy BairChief Legal OfficerSale31,487$12.63$398KForm 4
Aug 17, 2026Troy Edward WilsonCEOPurchase100,000$11.12$1.1MForm 4
Jun 18, 2026Mollie LeoniChief Medical OfficerSale84,929$9.82$834KForm 4
May 21, 2026Brian T. PowlChief Commercial OfficerSale10,000$11.00$110KForm 4
May 19, 2026Brian T. PowlChief Commercial OfficerSale339$9.21$3.1KForm 4
May 19, 2026Kathleen FordChief Operating OfficerSale2,257$9.08$20.5KForm 4
May 18, 2026Teresa Brophy BairChief Legal OfficerSale2,256$9.38$21.2KForm 4
Jan 27, 2026Brian T. PowlChief Commercial OfficerSale1,572$8.46$13.3KForm 4
Jan 27, 2026Brian T. PowlChief Commercial OfficerSale4,842$8.46$41KForm 4
Jan 27, 2026Francis BurrowsChief Scientific OfficerSale1,311$8.46$11.1KForm 4
Jan 27, 2026Kathleen FordChief Operating OfficerSale1,813$8.46$15.3KForm 4
Jan 27, 2026Mollie LeoniChief Medical OfficerSale1,341$8.46$11.3KForm 4
Jan 27, 2026Mollie LeoniChief Medical OfficerSale951$8.46$8KForm 4
Jan 27, 2026Mollie LeoniChief Medical OfficerSale3,655$8.46$30.9KForm 4
Jan 27, 2026Mollie LeoniChief Medical OfficerSale2,233$8.46$18.9KForm 4
Jan 27, 2026Thomas James DoyleVice presidentSale1,114$8.46$9.4KForm 4
Jan 27, 2026Thomas James DoyleVice presidentSale695$8.46$5.9KForm 4
Jan 27, 2026Thomas James DoyleVice presidentSale2,226$8.46$18.8KForm 4
Jan 27, 2026Thomas James DoyleVice presidentSale881$8.46$7.5KForm 4
Jan 27, 2026Teresa Brophy BairChief Legal OfficerSale4,777$8.46$40.4KForm 4
Jan 27, 2026Teresa Brophy BairChief Legal OfficerSale2,335$8.46$19.8KForm 4
Jan 27, 2026Teresa Brophy BairChief Legal OfficerSale4,096$8.46$34.7KForm 4
Dec 18, 2025Francis BurrowsChief Scientific OfficerSale23,726$9.78$232KForm 4
Dec 9, 2025Faheem HasnainDirectorSale10,000$10.98$110KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Troy Edward WilsonPresident and CEO, Director$3.9M–Nov 16, 2026
Mollie LeoniChief Medical Officer–$1.3MSep 29, 2026
Teresa Brophy BairChief Legal Officer–$602KSep 28, 2026
Brian T. PowlChief Commercial Officer–$564KSep 29, 2026
Francis BurrowsChief Scientific Officer–$468KSep 24, 2026
Kathleen FordChief Operating Officer–$148KSep 29, 2026
Faheem HasnainDirector–$110KDec 9, 2025
Thomas James DoyleSVP, Finance & Accounting–$90KSep 28, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

KURA short interest

High short interest. 14.2% of KURA shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 19%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.64M KURA shares were sold short, 14.2% of the shares outstanding, down 11.7% from the report before. At the average daily volume of 1.61M shares, buying them all back would take about 7.9 trading days (days to cover).

Shares short, % of all shares

14.2%May 15Oct 3018.2%

Days to cover

7.9May 15Oct 3012.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.64M14.21%-12%1.61M7.9
Oct 15, 202614.32M16.10%-1%1.67M8.6
Sep 30, 202614.42M16.21%-3%1.86M7.7
Sep 15, 202614.82M16.66%+10%1.69M8.8
Aug 31, 202613.42M15.08%+2%2.80M4.8
Aug 14, 202613.12M14.75%-0%1.49M8.8
Jul 31, 202613.16M14.90%-4%1.11M11.8
Jul 15, 202613.73M15.55%-9%1.78M7.7
Jun 30, 202615.09M17.09%+3%1.76M8.6
Jun 15, 202614.60M16.53%+7%1.99M7.3
May 29, 202613.59M15.39%-13%2.55M5.3
May 15, 202615.64M17.71%+1%1.37M11.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Kura Oncology company events

Kura Oncology filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 9, 2026AnnouncementSubsidiary Financing Kura Oncology, Inc. formed a wholly owned subsidiary, Caspian Therapeutics, Inc., to focus on the development of next-generation menin inhibitors for the treatment of diabetes and other cardiometabolic diseases. Filing
  3. Sep 8, 2026LeadershipThe Board of Directors of Kura Oncology, Inc. appointed Jennifer Fulk as the Company’s Chief Financial Officer, principal financial officer (replacing Troy E. Wilson, Ph.D., J.D. solely with respect to such role) and principal accounting officer (replacing Thomas Doyle solely with respect to such… Filing
  4. Aug 12, 2026ResultsReleased financial results. Filing
  5. Jul 29, 2026LeadershipKura Oncology, Inc. entered into a Second Amended and Restated Executive Employment Agreement with Troy E. Wilson, Ph.D., J.D., the Company’s Chairman, President and Chief Executive Officer to, among other things, modify certain severance provisions. Filing
  6. Jun 4, 2026LeadershipOur Board of Directors, upon the recommendation of the Compensation Committee of the Board, amended the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan, in each case subject to stockholder approval, to, among other things, increase the… Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Mar 5, 2026ResultsReleased financial results. Filing
  9. Jan 29, 2026RulesChanged its bylaws or articles. Filing
  10. Jan 12, 2026ResultsReleased financial results. Filing
  11. Dec 2, 2025AnnouncementKura Oncology, Inc. announced the first U.S. commercial sale of KOMZIFTI ™ (ziftomenib) has been completed. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Kura Oncology financials

Famous investors that hold KURA

5 of the 50 well-known investors we track reported holding KURA in their latest 13F filing. The largest position is Jim Simons's, worth $21.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.01M$21.5M0.0%+21%
Ken Griffin · Citadel AdvisorsQ3 2026680,119$7.3M0.0%+107%
Ken Fisher · Fisher Asset ManagementQ3 2026565,300$6.1M0.0%-10%
Israel Englander · Millennium ManagementQ3 2026358,402$3.8M0.0%-50%
Paul Tudor Jones · Tudor Investment CorpQ3 202642,940$460K0.0%-1%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named KURA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A3.9%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A3.9%
Oct 27, 2026BlackRock, Inc.13G/A8.9%
Oct 27, 2026BlackRock, Inc.13G/A8.9%

Questions about Kura Oncology, Inc. (KURA) stock

Who owns the most KURA stock?

The largest reported owner of Kura Oncology, Inc. (KURA) is BlackRock, Inc., with 11.9% of the company. In total, 218 funds and institutions reported holding KURA at the end of Q2 2026, together about 99% of the shares. See the largest owners.

Are KURA insiders buying or selling?

In the last 12 months, KURA insiders reported 4 open-market purchases worth $3.9M and 34 sales worth $3.3M. The latest trade was on Nov 16, 2026. See every trade.

What is the short interest in KURA?

As of Oct 30, 2026, 12.64M KURA shares were sold short, 14.2% of the shares outstanding, down 11.7% from the report before. At the average daily volume of 1.61M shares, buying them all back would take about 7.9 trading days (days to cover). See the history.

Which famous investors hold KURA?

5 of the 50 well-known investors we track reported KURA in their latest 13F filing, including Jim Simons, Ken Griffin, Ken Fisher. The largest position is worth $21.5M. See all holders.

Executive pay

Kura Oncology's chief executive was paid a total of $4.7M for the year ended Dec 31, 2025, down 24% from $6.2M the year before. In the last 12 months, Kura Oncology's executives and directors bought $3.9M of stock on the open market and sold $3.3M.

Chief executive, total pay$4.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.